Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients

We review the current data on epidemiology, the clinical significance, the pathophysiologic mechanisms, and the treatment of VAs in the setting of COVID-19. VAs prevail in 0.15% to 8% of hospitalized patients, but only sustained and rapid tachyarrhythmias are purportedly associated with a significan...

Descripción completa

Detalles Bibliográficos
Autores principales: Tarantino, Nicola, Della Rocca, Domenico G., Zou, Fengwei, Lin, Aung, Natale, Andrea, Di Biase, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554003/
https://www.ncbi.nlm.nih.gov/pubmed/35221078
http://dx.doi.org/10.1016/j.ccep.2021.10.002
Descripción
Sumario:We review the current data on epidemiology, the clinical significance, the pathophysiologic mechanisms, and the treatment of VAs in the setting of COVID-19. VAs prevail in 0.15% to 8% of hospitalized patients, but only sustained and rapid tachyarrhythmias are purportedly associated with a significant increase in mortality. Multiple factors can elicit VAs, which are ultimately deemed to be a marker of severe systemic disease rather than a distinct cardiac condition. Even though the electrophysiologist plays a determinant role in the secondary prevention of VAs, a multidisciplinary approach is indispensable for primary prophylaxis and acute management.

Ejemplares similares